Clinical Trials
11 trialsNCT01525082 2024-02-06
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Stanford University
Phase 2 Completed
NCT05858177 2023-05-15
MPPGL
Peking Union Medical College Hospital
Phase 2 Completed
NCT03079440 2022-12-06
TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors
Asan Medical Center
Phase 2 Completed
NCT04122911 2020-10-26
TENEC
National Cancer Institute, Naples
Phase 2 Completed
NCT02698410 2020-10-01
ATLANT
Ipsen
Phase 2 Completed
NCT02248012 2019-12-19
Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)
Haukeland University Hospital
Phase 2 Completed
NCT02231762 2019-05-06
SONNET
Ipsen
Phase 2 Completed
NCT00869050 2016-07-25
Capecitabine and Temozolomide for Neuroendocrine Cancers
Columbia University
Phase 2 Completed
NCT01076530 2013-05-03
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00137774 2013-04-09
Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00165230 2009-04-28
Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors
Dana-Farber Cancer Institute
Phase 2 Completed